venetoclax,ibrutinib
abbvie,janssen,roche
['ibru', 'leukemia']
new imbruvica (ibrutinib) data in fixed-duration combination regimen presented at eha 2022 shows deep, durable response at three years in untreated chronic lymphocytic leukemia 
The pharma industry’s destination for news & analysis, fostering a comprehensive & collaborative community for pharma & healthcare marketing professionals.